U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H14N2
Molecular Weight 162.2319
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NICOTINE

SMILES

CN1CCC[C@@]1([H])c2cccnc2

InChI

InChIKey=SNICXCGAKADSCV-JTQLQIEISA-N
InChI=1S/C10H14N2/c1-12-7-3-5-10(12)9-4-2-6-11-8-9/h2,4,6,8,10H,3,5,7H2,1H3/t10-/m0/s1

HIDE SMILES / InChI

Molecular Formula C10H14N2
Molecular Weight 162.2319
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Sources: www.inchem.org/documents/pims/chemical/nicotine.htm
Curator's Comment:: description was created based on several sources, including https://cancercontrol.cancer.gov/brp/tcrb/monographs/1/index.html https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2928221/

Nicotine is a natural alkaloid obtained from the dried leaves and stems of the nightshade family of pants, such as Nicotiana tabacum and Nicotiana rustica, where it occurs in concentrations of 0.5-8%. Cigarette tobacco varies in its nicotine content, but common blends contain 15-25 mg per cigarette, with a current trend towards lower levels. Nicotine is highly addictive substance, it exhibits a stimulant effect when adsorbed at 2 mg. Administration of higher doses could be harmful. Action of nicotine is mediated by nicotinic cholinergic receptors. Nicotine binds to the interface between two subunits of the receptors, opens the channel and allows the entry of sodium or calcium. The principal mediator of nicotine dependence is α4β2 nicotine receptor.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
NICORETTE

Approved Use

Reduces withdrawal symptoms, including nicotine craving associated with quitting smoking

Launch Date

4.42713604E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
12 ng/mL
1 mg single, nasal
dose: 1 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
NICOTINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
6 ng × h/mL
1 mg single, nasal
dose: 1 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
NICOTINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3 min
1 mg single, nasal
dose: 1 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
NICOTINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
95%
1 mg single, nasal
dose: 1 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
NICOTINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
6 mg single, oral
Highest studied dose
Dose: 6 mg
Route: oral
Route: single
Dose: 6 mg
Sources:
healthy, 19 - 49 years
n = 44
Health Status: healthy
Condition: adult smokers
Age Group: 19 - 49 years
Sex: M+F
Population Size: 44
Sources:
Disc. AE: Bradycardia...
AEs leading to
discontinuation/dose reduction:
Bradycardia (1 patient)
Sources:
4 mg single, oral
Studied dose
Dose: 4 mg
Route: oral
Route: single
Dose: 4 mg
Sources:
healthy, 19 - 49 years
n = 44
Health Status: healthy
Condition: adult smokers
Age Group: 19 - 49 years
Sex: M+F
Population Size: 44
Sources:
Disc. AE: Allergic dermatitis...
AEs leading to
discontinuation/dose reduction:
Allergic dermatitis (1 patient)
Sources:
6 mg 1 times / hour steady, oral
Highest studied dose
Dose: 6 mg, 1 times / hour
Route: oral
Route: steady
Dose: 6 mg, 1 times / hour
Sources:
healthy, 19 - 50 years
n = 50
Health Status: healthy
Condition: adult smokers
Age Group: 19 - 50 years
Sex: M+F
Population Size: 50
Sources:
Disc. AE: Hypersensitivity, Nausea...
AEs leading to
discontinuation/dose reduction:
Hypersensitivity (1 patient)
Nausea (1 patient)
Sources:
8 mg 1 times / hour steady, oral
Highest studied dose
Dose: 8 mg, 1 times / hour
Route: oral
Route: steady
Dose: 8 mg, 1 times / hour
Sources:
healthy, 19 - 50 years
n = 50
Health Status: healthy
Condition: adult smokers
Age Group: 19 - 50 years
Sex: M+F
Population Size: 50
Sources:
Disc. AE: Depression, Nausea...
AEs leading to
discontinuation/dose reduction:
Depression (1 patient)
Nausea (grade 2-3, 2 patients)
Sources:
111 mg single, transdermal
Overdose
Dose: 111 mg
Route: transdermal
Route: single
Dose: 111 mg
Sources:
healthy, 41 years
n = 1
Health Status: healthy
Condition: adult smoker
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Death...
AEs leading to
discontinuation/dose reduction:
Death (grade 5, 1 patient)
Sources:
84 mg 1 times / day steady, transdermal
Highest studied dose
Dose: 84 mg, 1 times / day
Route: transdermal
Route: steady
Dose: 84 mg, 1 times / day
Sources:
healthy, adult
n = 36
Health Status: healthy
Condition: adult smokers
Age Group: adult
Sex: unknown
Population Size: 36
Sources:
Other AEs: Nausea...
AEs

AEs

AESignificanceDosePopulation
Bradycardia 1 patient
Disc. AE
6 mg single, oral
Highest studied dose
Dose: 6 mg
Route: oral
Route: single
Dose: 6 mg
Sources:
healthy, 19 - 49 years
n = 44
Health Status: healthy
Condition: adult smokers
Age Group: 19 - 49 years
Sex: M+F
Population Size: 44
Sources:
Allergic dermatitis 1 patient
Disc. AE
4 mg single, oral
Studied dose
Dose: 4 mg
Route: oral
Route: single
Dose: 4 mg
Sources:
healthy, 19 - 49 years
n = 44
Health Status: healthy
Condition: adult smokers
Age Group: 19 - 49 years
Sex: M+F
Population Size: 44
Sources:
Hypersensitivity 1 patient
Disc. AE
6 mg 1 times / hour steady, oral
Highest studied dose
Dose: 6 mg, 1 times / hour
Route: oral
Route: steady
Dose: 6 mg, 1 times / hour
Sources:
healthy, 19 - 50 years
n = 50
Health Status: healthy
Condition: adult smokers
Age Group: 19 - 50 years
Sex: M+F
Population Size: 50
Sources:
Nausea 1 patient
Disc. AE
6 mg 1 times / hour steady, oral
Highest studied dose
Dose: 6 mg, 1 times / hour
Route: oral
Route: steady
Dose: 6 mg, 1 times / hour
Sources:
healthy, 19 - 50 years
n = 50
Health Status: healthy
Condition: adult smokers
Age Group: 19 - 50 years
Sex: M+F
Population Size: 50
Sources:
Depression 1 patient
Disc. AE
8 mg 1 times / hour steady, oral
Highest studied dose
Dose: 8 mg, 1 times / hour
Route: oral
Route: steady
Dose: 8 mg, 1 times / hour
Sources:
healthy, 19 - 50 years
n = 50
Health Status: healthy
Condition: adult smokers
Age Group: 19 - 50 years
Sex: M+F
Population Size: 50
Sources:
Nausea grade 2-3, 2 patients
Disc. AE
8 mg 1 times / hour steady, oral
Highest studied dose
Dose: 8 mg, 1 times / hour
Route: oral
Route: steady
Dose: 8 mg, 1 times / hour
Sources:
healthy, 19 - 50 years
n = 50
Health Status: healthy
Condition: adult smokers
Age Group: 19 - 50 years
Sex: M+F
Population Size: 50
Sources:
Death grade 5, 1 patient
Disc. AE
111 mg single, transdermal
Overdose
Dose: 111 mg
Route: transdermal
Route: single
Dose: 111 mg
Sources:
healthy, 41 years
n = 1
Health Status: healthy
Condition: adult smoker
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Nausea
84 mg 1 times / day steady, transdermal
Highest studied dose
Dose: 84 mg, 1 times / day
Route: transdermal
Route: steady
Dose: 84 mg, 1 times / day
Sources:
healthy, adult
n = 36
Health Status: healthy
Condition: adult smokers
Age Group: adult
Sex: unknown
Population Size: 36
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

Drug as perpetrator​Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Modulation of phosphatidylinositol turnover on central nicotinic receptors.
1997 Jul
Nicotine potentiates sulpiride-induced catalepsy in mice.
1998
Ginseng total saponin inhibits nicotine-induced hyperactivity and conditioned place preference in mice.
1999 Jul
Predictors and timing of adverse experiences during trandsdermal nicotine therapy.
1999 Jun
Selective alpha 7 nicotinic receptor stimulation normalizes chronic cocaine-induced loss of hippocampal sensory inhibition in C3H mice.
1999 Nov 15
Mimicking gene defects to treat drug dependence.
2000
Analgesic and toxic effects of ABT-594 resemble epibatidine and nicotine in rats.
2000 Apr
Transdermal nicotine mimics the smoking-induced endothelial dysfunction.
2000 Aug
Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans.
2000 Jan
Regional and cellular induction of nicotine-metabolizing CYP2B1 in rat brain by chronic nicotine treatment.
2000 Jun 15
[A comparative study of the central H-cholinergic-blocking and NMDA-blocking actions of MK-801, memantin, amantadine, pyrilen and IEM-1754 in experiments on intact rats].
2000 Mar-Apr
Kynurenic acid does not protect against nicotine-induced seizures in mice.
2000 Nov-Dec
Prenatal nicotine exposure is associated with an increase in [125I]epibatidine binding in discrete cortical regions in rats.
2000 Oct
Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking.
2000 Oct
Evidence that nicotinic alpha(7) receptors are not involved in the hyperlocomotor and rewarding effects of nicotine.
2000 Sep
Effect of nicotine on fibroblast beta 1 integrin expression and distribution in vitro.
2001 Apr
Nicotine inhibits UV-induced activation of the apoptotic pathway.
2001 Dec 15
Tolerance to nicotine's effects in the elevated plus-maze and increased anxiety during withdrawal.
2001 Feb
Nicotine self-administration and withdrawal: modulation of anxiety in the social interaction test in rats.
2001 Jan
Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro.
2001 Jun
Reversal of diminished inhibitory sensory gating in cocaine addicts by a nicotinic cholinergic mechanism.
2001 Jun
Smoking and balance: correlation of nicotine-induced nystagmus and postural body sway.
2001 May 8
Comparison of cytochrome P450 2A6 polymorphism frequencies in Caucasians and African-Americans using a new one-step PCR-RFLP genotyping method.
2001 Nov 30
Activation of 5-HT(2C) receptors reduces the locomotor and rewarding effects of nicotine.
2001 Sep
Microsomal N-glucuronidation of nicotine and cotinine: human hepatic interindividual, human intertissue, and interspecies hepatic variation.
2002 Dec
Increased sensitivity to nicotine-induced seizures in mice heterozygous for the L250T mutation in the alpha7 nicotinic acetylcholine receptor.
2002 Feb 11
Enhancement of cocaine-seeking behavior by repeated nicotine exposure in rats.
2002 Jul
Involvement of human heat shock protein 90 alpha in nicotine-induced apoptosis.
2002 Jul 1
The selectively bred high alcohol sensitivity (HAS) and low alcohol sensitivity (LAS) rats differ in sensitivity to nicotine.
2002 Jun
N-n-alkylnicotinium analogs, a novel class of nicotinic receptor antagonist: inhibition of S(-)-nicotine-evoked [(3)H]dopamine overflow from superfused rat striatal slices.
2002 Jun
Increased sensitivity to nicotine-induced seizures in mice expressing the L250T alpha 7 nicotinic acetylcholine receptor mutation.
2002 Mar
Nicotine potentiation of morphine-induced catalepsy in mice.
2002 May
Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism.
2002 Nov
CYP2A6 genetic variation and potential consequences.
2002 Nov 18
beta 2 nicotinic acetylcholine receptor subunit modulates protective responses to stress: A receptor basis for sleep-disordered breathing after nicotine exposure.
2002 Oct 1
N-glucuronidation of nicotine and cotinine in human: formation of cotinine glucuronide in liver microsomes and lack of catalysis by 10 examined UDP-glucuronosyltransferases.
2002 Sep
Oral caffeine maintenance potentiates the reinforcing and stimulant subjective effects of intravenous nicotine in cigarette smokers.
2003 Jan
Nicotinic acetylcholine receptors and the regulation of neuronal signalling.
2004 Jun
How much nicotine kills a human? Tracing back the generally accepted lethal dose to dubious self-experiments in the nineteenth century.
2014 Jan
Patents

Sample Use Guides

Reduces withdrawal symptoms, including nicotine craving associated with quitting smoking, nicotine is available as a chewing gum, and is administered according to a schedule at doses 2-4 mg once every 2-4 hours. Nicotine is also available as a transdermal patch.
Route of Administration: Other
Functional activity of nicotine against hα4β2 nicotinic receptors was evaluated using the 86Rb+ ion flux assay in SH-EP1 cells, expressing hα4β2. The 86Rb+ efflux was measured using the “flip-plate” technique. Nicotine activated 86Rb+ efflux with EC50 of 290 nM.
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:58:06 UTC 2021
Edited
by admin
on Fri Jun 25 20:58:06 UTC 2021
Record UNII
6M3C89ZY6R
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
NICOTINE
EP   HSDB   ISO   MART.   MI   ORANGE BOOK   USP   VANDF   WHO-DD  
Systematic Name English
NICOTINE [HSDB]
Common Name English
NSC-5065
Code English
NICODERM CQ
Brand Name English
NICOTINE [ISO]
Common Name English
NICOTINE [MI]
Common Name English
PYRIDINE, 3-((2S)-1-METHYL-2-PYRROLIDINYL)-
Systematic Name English
NICOTINE [VANDF]
Common Name English
PROSTEP
Brand Name English
3-((2S)-1-METHYLPYRROLIDIN-2-YL)PYRIDINE
Systematic Name English
3-((2S)-1-METHYL-2-PYRROLIDINYL)PYRIDINE
Systematic Name English
HABITROL
Brand Name English
NICOTINUM
HPUS  
Common Name English
NICOTINE COMPONENT OF COMMIT
Brand Name English
NICOTINE [EP MONOGRAPH]
Common Name English
NICOTINE [USP MONOGRAPH]
Common Name English
NICOTINE [WHO-DD]
Common Name English
NICOTINUM [HPUS]
Common Name English
NICOTINE [ORANGE BOOK]
Common Name English
NICOTINE COMPONENT OF NICORETTE
Brand Name English
.BETA.-PYRIDYL-.ALPHA.-N-METHYL PYRROLIDINE
Common Name English
NICOTINE S(-)
Common Name English
NICOTROL
Brand Name English
NICOTINE [MART.]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C221
Created by admin on Fri Jun 25 20:58:06 UTC 2021 , Edited by admin on Fri Jun 25 20:58:06 UTC 2021
LIVERTOX 683
Created by admin on Fri Jun 25 20:58:06 UTC 2021 , Edited by admin on Fri Jun 25 20:58:06 UTC 2021
WHO-ATC N07BA01
Created by admin on Fri Jun 25 20:58:06 UTC 2021 , Edited by admin on Fri Jun 25 20:58:06 UTC 2021
NDF-RT N0000175706
Created by admin on Fri Jun 25 20:58:07 UTC 2021 , Edited by admin on Fri Jun 25 20:58:07 UTC 2021
WHO-VATC QP53AX13
Created by admin on Fri Jun 25 20:58:07 UTC 2021 , Edited by admin on Fri Jun 25 20:58:07 UTC 2021
WHO-VATC QN07BA01
Created by admin on Fri Jun 25 20:58:07 UTC 2021 , Edited by admin on Fri Jun 25 20:58:07 UTC 2021
EPA PESTICIDE CODE 56702
Created by admin on Fri Jun 25 20:58:06 UTC 2021 , Edited by admin on Fri Jun 25 20:58:06 UTC 2021
NDF-RT N0000006496
Created by admin on Fri Jun 25 20:58:06 UTC 2021 , Edited by admin on Fri Jun 25 20:58:06 UTC 2021
NCI_THESAURUS C73579
Created by admin on Fri Jun 25 20:58:06 UTC 2021 , Edited by admin on Fri Jun 25 20:58:06 UTC 2021
NDF-RT N0000006496
Created by admin on Fri Jun 25 20:58:07 UTC 2021 , Edited by admin on Fri Jun 25 20:58:07 UTC 2021
Code System Code Type Description
MESH
D009538
Created by admin on Fri Jun 25 20:58:06 UTC 2021 , Edited by admin on Fri Jun 25 20:58:06 UTC 2021
PRIMARY
RXCUI
7407
Created by admin on Fri Jun 25 20:58:07 UTC 2021 , Edited by admin on Fri Jun 25 20:58:07 UTC 2021
PRIMARY
IUPHAR
2585
Created by admin on Fri Jun 25 20:58:06 UTC 2021 , Edited by admin on Fri Jun 25 20:58:06 UTC 2021
PRIMARY
NCI_THESAURUS
C691
Created by admin on Fri Jun 25 20:58:06 UTC 2021 , Edited by admin on Fri Jun 25 20:58:06 UTC 2021
PRIMARY
PUBCHEM
89594
Created by admin on Fri Jun 25 20:58:07 UTC 2021 , Edited by admin on Fri Jun 25 20:58:07 UTC 2021
PRIMARY
HSDB
1107
Created by admin on Fri Jun 25 20:58:06 UTC 2021 , Edited by admin on Fri Jun 25 20:58:06 UTC 2021
PRIMARY
WIKIPEDIA
NICOTINE
Created by admin on Fri Jun 25 20:58:07 UTC 2021 , Edited by admin on Fri Jun 25 20:58:07 UTC 2021
PRIMARY
ChEMBL
CHEMBL3
Created by admin on Fri Jun 25 20:58:06 UTC 2021 , Edited by admin on Fri Jun 25 20:58:06 UTC 2021
PRIMARY
DRUG BANK
DB00184
Created by admin on Fri Jun 25 20:58:06 UTC 2021 , Edited by admin on Fri Jun 25 20:58:06 UTC 2021
PRIMARY
EPA CompTox
54-11-5
Created by admin on Fri Jun 25 20:58:06 UTC 2021 , Edited by admin on Fri Jun 25 20:58:06 UTC 2021
PRIMARY
EVMPD
SUB14645MIG
Created by admin on Fri Jun 25 20:58:06 UTC 2021 , Edited by admin on Fri Jun 25 20:58:06 UTC 2021
PRIMARY
LACTMED
Nicotine
Created by admin on Fri Jun 25 20:58:06 UTC 2021 , Edited by admin on Fri Jun 25 20:58:06 UTC 2021
PRIMARY
CAS
54-11-5
Created by admin on Fri Jun 25 20:58:06 UTC 2021 , Edited by admin on Fri Jun 25 20:58:06 UTC 2021
PRIMARY
EVMPD
SUB30160
Created by admin on Fri Jun 25 20:58:06 UTC 2021 , Edited by admin on Fri Jun 25 20:58:06 UTC 2021
PRIMARY
DRUG CENTRAL
1920
Created by admin on Fri Jun 25 20:58:06 UTC 2021 , Edited by admin on Fri Jun 25 20:58:06 UTC 2021
PRIMARY
MERCK INDEX
M7879
Created by admin on Fri Jun 25 20:58:06 UTC 2021 , Edited by admin on Fri Jun 25 20:58:06 UTC 2021
PRIMARY Merck Index
FDA UNII
6M3C89ZY6R
Created by admin on Fri Jun 25 20:58:06 UTC 2021 , Edited by admin on Fri Jun 25 20:58:06 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-193-3
Created by admin on Fri Jun 25 20:58:06 UTC 2021 , Edited by admin on Fri Jun 25 20:58:06 UTC 2021
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
TARGET -> AGONIST
NICOTINE IS AN ANTIHERBIVORY ALKALOID AND POTENT PARASYMPATHOMIMETIC STIMULANT AND FOUND IN PLANTS, MOSTLY THOSE IN THE NIGHTSHADE FAMILY. NICOTINE ACTS AS A RECEPTOR AGONIST AT MOST NICOTINIC ACETYLCHOLINE RECEPTORS (NACHRS), EXCEPT AT TWO NICOTINIC RECEPTOR SUBUNITS (NACHR.ALPHA.9 AND NACHR.ALPHA.10) WHERE IT ACTS AS A RECEPTOR ANTAGONIST.
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
USP
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
BINDER->LIGAND
BINDING
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
SUB_CONCEPT->SUBSTANCE
SALT/SOLVATE -> PARENT
PARENT -> CONSTITUENT ALWAYS PRESENT
Nicotine (mg/cigarette) Domestic = 12.6 SD(1.6) Imported = 11.1 SD(2.2)
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
LABELED -> NON-LABELED
SUB_CONCEPT->SUBSTANCE
Related Record Type Details
METABOLITE LESS ACTIVE -> PARENT
75% is converted into cotintine which is further metabolized.
MAJOR
PLASMA; URINE
METABOLITE -> PARENT
circulating nicotine is metabolized to cotinine by cytochrome P450 and aldehyde oxidase
MAJOR
METABOLITE -> PARENT
in animals both N-oxide isomers form, in humans only the transisomers form.
MAJOR
URINE
METABOLITE -> PARENT
The extent of nicotine N-glucuronidation by African Americans is significantly lower than by Whites.
METABOLITE -> PARENT
PLASMA; URINE
METABOLITE -> PARENT
The extent of Cotinine N-glucuronidation by African Americans is significantly lower than by Whites.
METABOLITE INACTIVE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC